Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
NEW YORK, March 07, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Cardiovascular Systems, Inc. (NASDAQ:CSII) securities between September 12, 2011 and January 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cardiovascular-systems. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cardiovascular-systems.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
